Hodgkin Lymphoma 
Welcome,         Profile    Billing    Logout  

173 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Hodgkin Lymphoma
2020-001856-16: Evaluation of the Relationship Between Therapeutical Antibody Exposure and Tumor VOLUME in Patients Treated for Conventional HODgkin's Lymphoma Evaluation de la RElation entre exposition à un anticorps thérapeutique et VOLUme tumoral chez le patient traité pour un lyMphome de HODgkin classique

Not yet recruiting
4
50
Europe
OPDIVO, KEYTRUDA, BMS-936558, Concentrate for solution for infusion, OPDIVO, KEYTRUDA
Rennes University Hospital, Cancer Translational Research Program
Refractory Hodgkin Lymphoma Lymphome de Hodgkin réfractaire, Hodgkin Lymphoma Lymphome de Hodgkin, Diseases [C] - Cancer [C04]
 
 
2020-004780-71: A study using a hormone drug during chemotherapy for fertility protection of young women and teenagers with cancer - ProFertil En studie med ett hormonpreparat som utvärderar effekten av fertilitet hos unga kvinnor och tonåringar med cancer - ProFertil

Not yet recruiting
3
500
Europe
Pamorelin, Powder and solvent for prolonged-release suspension for injection, Pamorelin
Karolinska University Hospital, Karolinska University Hospital
Breast CancerAcute LeukemiaLymphomas (Hodgkin and non-Hodgkin)Sarcomas (Osteo, Soft tissue and Ewing) Bröstcancer, Akut Leukemi, Lymfom (Hodgkin och non-Hodgkin), Sarkom (Ben, Mjukvävnad och Ewing), Breast CancerBlood CancerCancer in lymphnodesCancer in bones Bröstcancer, Blodcancer, Cancer i lymfkörtlar, Cancer i skelett, Diseases [C] - Cancer [C04]
 
 
ECHELON-1 , NCT01712490 / 2011-005450-60: A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma

Checkmark Six year data from ECHELON-1 study for advanced classical Hodgkin lymphoma
Jul 2022 - Jul 2022: Six year data from ECHELON-1 study for advanced classical Hodgkin lymphoma
Checkmark Full data from ECHELON-1 trial in Hodgkin lymphoma at ASCO 2022
May 2022 - May 2022: Full data from ECHELON-1 trial in Hodgkin lymphoma at ASCO 2022
Checkmark Five-year data from ECHELON-1 trial for hodgkin lymphoma at ASH 2020
More
Active, not recruiting
3
1334
Europe, Canada, Japan, US, RoW
brentuximab vedotin, ADCETRIS®, SGN-35, doxorubicin, Adriamycin, bleomycin, vinblastine, dacarbazine, DTIC
Takeda, Seagen Inc.
Hodgkin Lymphoma
04/17
01/26
2022-000371-39: MK-4280A versus Physician’s Choice Chemotherapy in PD-(L)1-refractory, relapsed/refractory Classical Hodgkin Lymphoma

Ongoing
3
360
Europe
MK4280A (Favezelimab + Pembrolizumab), MK4280A, Solution for infusion, Bendamustine, Gemcitabine
Merck Sharp & Dohme LLC, Merck Sharp & Dohme LLC
PD-(L)1-refractory, Relapsed or Refractory Classical Hodgkin Lymphoma, Relapsed or Refractory Classical Hodgkin Lymphoma, Diseases [C] - Cancer [C04]
 
 
NCT04044222: A Study to Evaluate the Efficacy and Safety of a Sintilimab Plus ICE Regimen Versus ICE Regimen in Classic Hodgkin's Lymphoma Patients (cHL) Who Have Failed First-line Standard Chemotherapy

Recruiting
3
240
RoW
Sintilimab, Carboplatin, Etoposide, Ifosfamide, Placebo
Innovent Biologics (Suzhou) Co. Ltd.
Classic Hodgkin's Lymphoma
07/23
12/24
NCT04342936: Study of Camrelizumab (SHR-1210) vs. Chemotherapy in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma

Recruiting
3
56
RoW
Camrelizumab, SHR-1210, Investigator's choice of Chemotherapy
Jiangsu HengRui Medicine Co., Ltd.
Classical Hodgkin Lymphoma
08/23
12/23
ReSPECT, NCT04368559 / 2017-004981-85: Study of Rezafungin Compared to Standard Antimicrobial Regimen for Prevention of Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow Transplantation

Recruiting
3
462
Europe, Canada, US, RoW
Rezafungin for Injection, Intravenous antifungal therapy, Posaconazole, Noxafil, Fluconazole, Generic Fluconazole, Trimethoprim-sulfamethoxazole (TMP/SMX), Bactrim, Septra, Intravenous Placebo, Placebo Infusion, Oral Placebo, encapsulated cellulose
Cidara Therapeutics Inc.
Candidemia, Mycoses, Fungal Infection, Fungemia, Invasive Candidiasis, Pneumocystis, Mold Infection, Invasive Fungal Disease, Prophylaxis of Invasive Fungal Infections, Aspergillus
08/24
08/24
RATIONALE-314, NCT04486391: Tislelizumab Monotherapy Versus Salvage Chemotherapy for Relapsed/Refractory Classical Hodgkin Lymphoma

Recruiting
3
123
RoW
Tislelizumab, BGB-A317, Salvage Chemotherapy
BeiGene
Classical Hodgkin Lymphoma
09/24
03/25
OPTIMAL>60, NCT01478542 / 2010-019587-36: / DR. CHOP, Improvement of Therapy of Elderly Patients With CD20+ DLBCL Using Rituximab Optimized and Liposomal Vincristine

Checkmark ASH 2014
Nov 2014 - Nov 2014: ASH 2014
Checkmark P3 enrollment initiation in 1st line, adult NHL pts
Nov 2011 - Nov 2011: P3 enrollment initiation in 1st line, adult NHL pts
Completed
3
1152
Europe
Conventional Vincristine, Liposomal Vincristine, Ricover-scheme rituximab, optimised rituximab-schedule
Universität des Saarlandes, German High-Grade Non-Hodgkin's Lymphoma Study Group, Spectrum Pharmaceuticals, Inc
CD20+ Aggressive B-Cell Lymphoma
01/24
01/24
E-CELERATE, NCT05181540: A Study of the Effects of AB-205 in Patients With Lymphoma Undergoing Autologous Hematopoietic Cell Transplantation

Terminated
3
130
US
AB-205, E-CEL cells, Placebo
Angiocrine Bioscience, California Institute for Regenerative Medicine (CIRM)
Hodgkin Lymphoma, Non Hodgkin Lymphoma
12/23
01/24
NCT05518318: GLS-010 Monotherapy Versus Chemotherapy in Patients With Relapsed or Refractory Classical Hodgkin's Lymphoma (R/R cHL)

Not yet recruiting
3
60
NA
GLS-010, GLS-010 therapy, Chemotherapy of Investigator's choice
Guangzhou Gloria Biosciences Co., Ltd.
Classic Hodgkin's Lymphoma, Recurrent Classic Hodgkin Lymphoma, Refractory Classic Hodgkin Lymphoma
06/25
06/25
KEYNOTE-204, NCT02684292 / 2015-005053-12: Study of Pembrolizumab (MK-3475) vs. Brentuximab Vedotin in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (MK-3475-204/)

Checkmark From KEYNOTE-204 trial in r/r classical Hodgkin’s lymphoma
Feb 2022 - Feb 2022: From KEYNOTE-204 trial in r/r classical Hodgkin’s lymphoma
Checkmark Expanded label in Keytruda for treatment of patients with classical Hodgkin lymphoma (cHL) after prior therapies
Mar 2021 - Mar 2021: Expanded label in Keytruda for treatment of patients with classical Hodgkin lymphoma (cHL) after prior therapies
Checkmark Efficiancy & safety data from KEYNOTE-204 study compared to brentuximab vedotin for r/r chronic Hodgkin's lymphoma
More
Active, not recruiting
3
304
NA
pembrolizumab, MK-3475, KEYTRUDA®, brentuximab vedotin, ADCETRIS®
Merck Sharp & Dohme LLC
Hodgkin Lymphoma
07/25
07/25
NCT05244642: A Phase III Study to Evaluate the Efficacy and Safety of Penpulimab in the Relapsed and Refractory Classical Hodgkin's Lymphoma

Recruiting
3
60
RoW
Penpulimab, AK105, Investigator's choice of Chemotherapy
Akeso, Beijing Cancer Hospital
Hodgkin Disease Lymphoma
12/25
03/26
BELINDA, NCT03570892 / 2016-002966-29: Tisagenlecleucel in Adult Patients With Aggressive B-cell Non-Hodgkin Lymphoma

Checkmark From BELINDA trial for 2L DLBCL [Did not met primary end point]
Aug 2021 - Aug 2021: From BELINDA trial for 2L DLBCL [Did not met primary end point]
Active, not recruiting
3
331
Europe, Japan, US, RoW
Tisagenlecleucel after optional bridging and lymphodepleting chemotherapy, Platinum-based immunochemotherapy followed in responding patients with high dose chemotherapy and autologous hematopoietic stem cell transplant (HSCT)
Novartis Pharmaceuticals
Non-Hodgkin Lymphoma
02/26
02/26
EPCORE DLBCL-2, NCT05578976 / 2021-000168-31: A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)

Recruiting
3
900
Europe, Canada, Japan, US, RoW
Epcoritamab, ABBV-GMAB-3013, Cyclophosphamide, Rituximab, Vincristine, Doxorubicin, Prednisone
Genmab, AbbVie
Diffuse Large B-Cell Lymphoma
01/27
12/29
ARCHED, NCT05820841: Acalabrutinib in Combination With R-miniCHOP in Older Adults With Untreated Diffuse Large B-Cell Lymphoma

Recruiting
3
330
Europe
R-miniCHOP + Acalabrutinib, R-miniCHOP
Universität des Saarlandes, University of Leipzig, University Hospital Regensburg, Wuerzburg University Hospital, University Hospital of Gießen and Marburg, Saarland University Medical Center, AstraZeneca
Large B-cell Lymphoma, Diffuse Large B Cell Lymphoma
04/28
12/28
RADAR, NCT04685616: Brentuximab Vedotin in Early Stage Hodgkin Lymphoma

Recruiting
3
1042
Europe, US, RoW
Involved site radiotherapy, Doxorubicin, Bleomycin, Brentuximab vedotin, Vinblastine, Dacarbazine, Haematopoietic growth factor, Filgrastim, G-CSF, Pegfilgrastim
University College, London, Takeda, University of Miami, European Organisation for Research and Treatment of Cancer - EORTC, Australasian Leukaemia and Lymphoma Group, Seagen Inc., Canadian Cancer Trials Group
Hodgkin Lymphoma
09/30
09/32
KEYFORM-008, NCT05508867 / 2022-000371-39: A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Physician's Choice Chemotherapy in PD-(L)1-refractory, Relapsed or Refractory Classical Hodgkin Lymphoma (MK-4280A-008)

Recruiting
3
360
Europe, Canada, US, RoW
favezelimab/pembrolizumab, MK-4820A, bendamustine, BENDEKA®, gemcitabine, GEMZAR®
Merck Sharp & Dohme LLC, Merck Sharp & Dohme LLC
Hodgkin Lymphoma
05/27
06/31
2011-005562-38: Safety and Efficacy of peripheral blood stem cell transplantation using specifically purified stem cell preparations derived from patient family members in paediatric and adult patients Sicherheit und Wirksamkeit der Blutstammzelltransplantation mit spezifisch aufgereinigten Stammzellpräparaten von Famililienmitgliedern der Patienten als Spender bei Kindern und Erwachsenen

Ongoing
2
60
Europe
TCRabCD19PBSC, TCRabCD19PBSC_cryo, Suspension for injection
Miltenyi Biotec GmbH, Miltenyi Biotec GmbH
Hematological and non-hematological malignancies, and non-malignant diseases, requiring allogeneic blood stem cell transplantation without available HLA-identical donor. Hämatologische oder nicht-hämatologische maligne Erkrankungen oder nicht bösartige Erkrankungen, die einer allogenen Blutstammzelltransplantation eines haploidentischen Spenders bedürfen., Severe diseases requiring allogenic blood stem cell transplantation. Schwere Erkrankungen, die einer allogenen Blutstammzelltransplantation bedürfen., Diseases [C] - Cancer [C04]
 
 
2015-003318-26: Phase II, open-label, not comparative, multicenter study of multiple doses of NEPA (Netupitant+Palonosetron) in preventing chemotherapy induced nausea and vomiting(CINV) in patient with Non Hodgkin’s Lymphomareceiving salvage chemotherapy followed by high dose chemotherapy and autologous hematopoietic stem cells support. Studio di fase II, in aperto, non comparativo, multicentrico, di dosi ripetute di NEPA (netupitant + palonosetron) nella prevenzione della nausea ed il vomito indotti da chemioterapia (CINV) in pazienti con Linfoma Non-Hodgkin trattati con chemioterapia di salvataggio seguita da alte dosi di chemioterapia con supporto di cellule staminali ematopoietiche

Ongoing
2
81
Europe
AKYNZEO, EU/1/15/1001/001, Capsule, hard, AKYNZEO
ASSOCIAZIONE SALENTINA ANGELA SERRA ONLUS, ITALFARMACO S.P.A.
NON HODGKIN'S LYMPHOMA LINFOMA NON HODGKIN, NON HODGKIN'S LYMPHOMA LINFOMA NON HODGKIN, Diseases [C] - Cancer [C04]
 
 
2017-002544-32: A phase II study of nivolumab monotherapy in patients with relapsed/refractory Hodgkin lymphoma fit for autologous stem cell transplant who fail to reach complete metabolic remission after first or second line salvage therapy

Not yet recruiting
2
120
Europe
Opdivo, BMS-936558, Concentrate for solution for infusion, Opdivo
University College London, Bristol-Myers Squibb Pharmaceuticals Ltd
Relapsed/refractory Hodgkin lymphoma, Hodgkin lymphoma is a cancer of the lymphatic system due to abnormal lymphocytes. Refractory means not responding to initial treatment. Relapse is where disease returns after initial response., Diseases [C] - Cancer [C04]
 
 
NCT02639559: Safety and Efficacy of BL-8040 for the Mobilization of Donor Hematopoietic Stem Cells and Allogeneic Transplantation in Patients With Advanced Hematological Malignancies

Completed
2
50
US
BL-8040, Leukapheresis, Hematopoietic cell transplant
Washington University School of Medicine, BioLineRx, Ltd.
Acute Myelogenous Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, Non-Hodgkin's Lymphoma, Non-Hodgkin Lymphoma, Hodgkin Disease, Hodgkins Disease, Hodgkin's Disease, Multiple Myeloma, Myelodysplastic Syndrome, Myeloproliferative Neoplasm
04/18
04/23
2018-002227-42: Avelumab in the frontline treatment of advanced classical Hodgkin lymphoma - a window study

Not yet recruiting
2
47
Europe
Avelumab, MSB0010718C, Concentrate for solution for infusion, Avelumab
University College London, Pfizer Limited
Advanced classical Hodgkin lymphoma, Advanced classical Hodgkin lymphoma is a cancer that causes the lymphocytes (a type of white blood cell involved in fighting infections) to grow abnormally., Diseases [C] - Cancer [C04]
 
 
2017-003334-82: Effect of Radiotherapy and Nivolumab in Relapsed classical Hodgkin Lymphoma Effekt von Radiotherapie und Nivolumab bei rezidiviertem klassischen Hodgkin Lymphom

Not yet recruiting
2
29
Europe
Nivolumab, Lyophilisate for solution for infusion, Opdivo
University of Cologne, Bristol-Myers Squibb, GHSG
Improvement of efficacy of nivolumab in patients with relapsed or refractory classical Hodgkin Lymphoma who recently progressed on anti-PD1 therapy., Improvement of efficacy of nivolumab in patients with relapsed or refractory classical Hodgkin Lymphoma who recently progressed on anti-PD1 therapy., Diseases [C] - Cancer [C04]
 
 
NU 16H08, NCT03226249: PET-Directed Therapy With Pembrolizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Classical Hodgkin Lymphoma

Active, not recruiting
2
30
US
Computed Tomography, CAT, CAT Scan, Computerized Axial Tomography, computerized tomography, CT, CT SCAN, tomography, Dacarbazine, 4-(Dimethyltriazeno)imidazole-5-carboxamide, 5-(Dimethyltriazeno)imidazole-4-carboxamide, Asercit, Biocarbazine, Dacarbazina, Dacarbazina Almirall, Dacarbazine - DTIC, Dacatic, Dakarbazin, Deticene, Detimedac, DIC, Dimethyl (triazeno) imidazolecarboxamide, Dimethyl Triazeno Imidazol Carboxamide, Dimethyl Triazeno Imidazole Carboxamide, dimethyl-triazeno-imidazole carboxamide, Dimethyl-triazeno-imidazole-carboximide, DTIC, DTIC-Dome, Fauldetic, Imidazole Carboxamide, Imidazole Carboxamide Dimethyltriazeno, WR-139007, Doxorubicin Hydrochloride, 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8, 9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S-cis)- (9CI), ADM, Adriacin, Adriamycin, Adriamycin Hydrochloride, Adriamycin PFS, Adriamycin RDF, ADRIAMYCIN, HYDROCHLORIDE, Adriamycine, Adriblastina, Adriblastine, Adrimedac, Chloridrato de Doxorrubicina, DOX, DOXO-CELL, Doxolem, Doxorubicin.HCl, Doxorubin, Farmiblastina, FI 106, FI-106, hydroxydaunorubicin, Rubex, Fludeoxyglucose F-18, 18FDG, FDG, fludeoxyglucose F 18, Fludeoxyglucose F18, Fluorine-18 2-Fluoro-2-deoxy-D-Glucose, Fluorodeoxyglucose F18, Laboratory Biomarker Analysis, Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, Vinblastine Sulfate, 29060 LE, 29060-LE, Exal, Velban, Velbe, Velsar, VINCALEUKOBLASTINE
Northwestern University, National Cancer Institute (NCI), Merck Sharp & Dohme LLC
Classical Hodgkin Lymphoma, Lymphocyte-Depleted Classical Hodgkin Lymphoma, Lymphocyte-Rich Classical Hodgkin Lymphoma, Mixed Cellularity Classical Hodgkin Lymphoma, Nodular Sclerosis Classical Hodgkin Lymphoma
05/19
10/24
2018-000873-59: A trial to improve disease control after an allogeneic stem cell transplantation for relapsed or refractory classical Hodgkin lymphoma with consolidation therapy by Brentuximab Vedotin

Not yet recruiting
2
21
Europe
Adcetris, Lyophilisate for solution for infusion, Adcetris
University of Cologne, Takeda Pharmaceutical Company Ltd.
disease control after an allogeneic stem cell transplantation (alloSCT) for relapsed or refractory classical Hodgkin lymphoma (rrHL, cHL) with consolidation therapy by Brentuximab Vedotin (BV), Diseases [C] - Cancer [C04]
 
 
2018-002492-17: Evaluation of a Treatment with tislelizumab and zanubrutinib in patients with a Richter Transformation. Bewertung einer Behandlung mit Tislelizumab und Zanubrutinib bei Patienten mit einer Richter-Transformation.

Not yet recruiting
2
48
Europe
Tislelizumab, Zanubrutinib, BGB-A317, BGB-3111, Concentrate and solvent for concentrate for solution for infusion, Capsule, Tislelizumab, Zanubrutinib
Universität zu Köln, BeiGene Ltd.
Patients with previously untreated Richter Transformation or patients who responded to up to one prior line of RT therapy, Patients with previously untreated Richter Transformation or patients who responded to up to one prior line of RT therapy, Diseases [C] - Cancer [C04]
 
 
2019-002746-21: A Randomized Phase IIb Study, Evaluating Efficacy of Salvage Therapy with ESHAP vsRandomized study to evaluate the efficacy of therapy with BrentuximabVedotin-Etoposide, Methylprednisolone, Cisplatin and Cytarabine (ESHAP)vs ESHAP in patients with Hodgkin's Lymphoma, followed by treatmentwith Brentuximab Vedotin in patients who reach metabolic response aftersalvage therapy Estudio aleatorizado para evaluar la eficacia de la terapia con Brentuximab Vedotin -Etopsido, Metilprednisolona, Cisplatino y Citarabina (ESHAP) vs ESHAP en pacientes con Linfoma de Hodgkin, seguido de tratamiento con Brentuximab Vedotin en pacientes que alcancen respuesta metablica tras la terapia de rescate

Ongoing
2
150
Europe, RoW
Powder for solution for infusion, Adcetris
Fundación GELTAMO, Grupo Español de linfomas y trasplante autologo de medula osea (GELTAMO), Takeda Pharmaceuticals
Patients with Relapsed /Refractory Classical Hodgkin's Lymphoma Pacientes con Linfoma de Hodgkin Clásico Refractario o en Recaída, Hodgkin’s Lymphoma Linfoma de Hodgkin, Diseases [C] - Blood and lymphatic diseases [C15]
 
 
2015-003128-30: Ibrutinib in relapsed lymphocyte-predominant Hodgkin lymphoma Ibrutinib zur Behandlung des rezidivierten nodulär Lymphozyten-prädominanten Hodgkin Lymphom

Not yet recruiting
2
36
Europe
Capsule, hard, Imbruvica
University of Cologne, JANSSEN-CILAG GmbH
relapsed lymphocyte-predominant Hodgkin lymphoma rezidiviertes nodulär Lymphozyten-prädominantes Hodgkin Lymphom, relapsed Hodgkin lymphoma (cancer of lymphatic system) Rückfall eines Hodgkin Lymphoms (Krebserkrankung des lymphatischen Systems), Diseases [C] - Cancer [C04]
 
 
NCT01920932: Adcetris (Brentuximab Vedotin), Combination Chemotherapy, and Radiation Therapy in Treating Younger Patients With Stage IIB, IIIB and IV Hodgkin Lymphoma

Active, not recruiting
2
77
US
brentuximab vedotin, SGN-35, Adcetris(R), etoposide, VP-16, Vepesid(R), prednisone, prednisolone, doxorubicin, Adriamycin(R), cyclophosphamide, Cytoxan(R), Dacarbazine(R), Dimethyl Triazeno Imidazole Carboximide (DTIC), filgrastim, Neupogen(R), quality of life assessment, radiation therapy, irradiation, radiotherapy, radiation
St. Jude Children's Research Hospital, Seagen Inc.
Stage II Childhood Hodgkin Lymphoma, Stage III Childhood Hodgkin Lymphoma, Stage IV Childhood Hodgkin Lymphoma
11/20
05/28
2019-003983-28: A phase 2 study of retreatment with brentuximab vedotin in subjects with classic Hodgkin lymphoma or CD30-expressing peripheral T cell lymphoma Studio di fase 2 di ritrattamento con brentuximab vedotin in soggetti affetti da linfoma di Hodgkin classico o linfoma periferico a cellule T CD30-positivo

Not yet recruiting
2
80
Europe
Brentuximab vedotin, [SGN-35], Powder for concentrate for solution for infusion, ADCETRIS®
SEAGEN INC., Seattle Genetics, Inc.
- classic Hodgkin lymphoma (cHL)- Systemic anaplastic large cell lymphoma (sALCL)- CD30-expressing peripheral T cell lymphoma (PTCL) - linfoma di Hodgkin classico (cHL)- Linfoma anaplastico sistemico a grandi cellule (sALCL)- Linfoma a cellule T periferiche che esprimono CD30 (PTCL), - Hodgkin lymphoma- Lymphoma- T cell lymphoma - Linfoma di Hodgkin- Linfoma- Linfoma a cellule T, Diseases [C] - Cancer [C04]
 
 
NU 16H07, NCT03077828: Pembrolizumab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma

Active, not recruiting
2
43
US
Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, Nealorin, Novoplatinum, Paraplat, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Etoposide, Demethyl Epipodophyllotoxin Ethylidine Glucoside, EPEG, Lastet, Toposar, Vepesid, VP 16-213, VP-16, VP-16-213, Ifosfamide, Asta Z 4942, Asta Z-4942, Cyfos, Holoxan, Holoxane, Ifex, IFO, IFO-Cell, Ifolem, Ifomida, Ifomide, Ifosfamidum, Ifoxan, IFX, Iphosphamid, Iphosphamide, Iso-Endoxan, Isoendoxan, Isophosphamide, Mitoxana, MJF 9325, MJF-9325, Naxamide, Seromida, Tronoxal, Z 4942, Z-4942, Laboratory Biomarker Analysis, Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475
Northwestern University, Merck Sharp & Dohme LLC, National Cancer Institute (NCI)
Lymphocyte-Rich Classical Hodgkin Lymphoma, Recurrent Lymphocyte-Depleted Classical Hodgkin Lymphoma, Recurrent Mixed Cellularity Classical Hodgkin Lymphoma, Recurrent Nodular Sclerosis Classical Hodgkin Lymphoma, Refractory Lymphocyte-Depleted Classical Hodgkin Lymphoma, Refractory Mixed Cellularity Classical Hodgkin Lymphoma, Refractory Nodular Sclerosis Classical Hodgkin Lymphoma
12/20
12/24
2020-005609-20: Study of Pembroliumab Given Every Six Weeks to Participants with rrcHL or rrPMBCL Klinické hodnocení fáze 2 zkoumající léčbu rrcHL nebo rrPMBCL přípravkem MK-3475 podávaným jednou za 6 týdnů

Not yet recruiting
2
60
RoW, Europe
-, MK-3475, Solution for infusion, KEYTRUDA® (Pembrolizumab, MK-3475)
Merck Sharp & Dohme LLC, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., MERCK SHARP & DOHME CORP. UNA SUSSIDIARIA DI MERCK & CO. INC., Merck Sharp & Dohme LLC, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
Relapsed or refractory Classical Hodgkins Lymphoma and relapsed or refractory Primary Large B-cell Lymphoma, Relapsed or refractory Classical Hodgkins Lymphoma and relapsed or refractory Primary Large B-cell, Diseases [C] - Cancer [C04]
 
 
NCT03800706: A Phase II Study to Evaluate the Safety and Efficacy of TQB2450 Injection in Relapsed or Refractory Classical Hodgkin's Lymphoma

Recruiting
2
85
RoW
TQB2450
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Safety and Effectiveness
06/21
12/21
2021-001244-95: Phase 2 study of pembrolizumab and chemotherapy in participants with classical Hodgkin Lymphoma that has just been diagnosed Estudio de fase 2 de pembrolizumab y quimioterapia en pacientes con linfoma de Hodgkin clásico de reciente diagnóstico

Ongoing
2
140
Europe
Solution for infusion, Concentrate for solution for infusion, Powder for solution for injection, Powder for solution for infusion, Solution for injection, Capsule, Tablet, KEYTRUDA (pembrolizumab, MK-3475), Doxorubicin-Ebewe, Vinblastin STADA®, Detimedac® 500 mg, BLEO-cell®, ETOPOSIDE EBEWE®, ENDOXAN 1 g, Cellcristin® 1 mg/ml, Natulan, Prednison HEXAL®, ETOPOSIDE, Prednison HEXAL® 20 mg, Doxorrubicina, Dacarbazina, Etopósido, Ciclofosfamida, Procarbazina, Prednisona, Bleomicina, Vincristina
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.,Inc
Classical Hodgkin Lymphoma Linfoma de Hodgkin clásico, Classical Hodgkin Lymphoma (cHL) is a type of cancer of the lymphatic system, which is a part of your immune system. cHL can appear in the lymph nodes and other parts of the body. El linfoma de Hodgkin clásico (LHc) es un tipo de cáncer del sistema linfático, que forma parte de su sistema inmunitario. El LHc puede aparecer en los ganglios linfáticos y otras partes del cuerpo., Diseases [C] - Cancer [C04]
 
 
2021-000870-27: A phase 2 trial to study safety and efficacy of Capivasertib in patients with blood cancer where disease or cancer cell grows after a period of remission or response to treatment does not last very long Ensayo de fase 2 para evaluar la seguridad y la eficacia del capivasertib en pacientes con cáncer de la sangre cuya enfermedad o las células del cáncer hayan vuelto a crecer tras un periodo de remisión o de respuesta al tratamiento de duración no muy prolongada

Not yet recruiting
2
272
Europe
Capivasertib, AZD5363, Tablet
AstraZeneca AB, AstraZeneca AB
Relapsed or Refractory B-cell Non-Hodgkin Lymphoma Linfoma no Hodgkin de células B en recidiva o refractario, Non-Hodgkin Lymphoma Linfoma no Hodgkin, Diseases [C] - Cancer [C04]
 
 
2020-005197-10: Nanatinostat and Valganciclovir in R/R EBV+ Lymphoma (“NAVAL-1”)

Not yet recruiting
2
150
Europe
Nanatinostat, Valganciclovir, ganciclovir, VRx-3996, Film-coated tablet, Powder for concentrate for solution for infusion, Valganciclovir hydrochloride
Viracta Therapeutics, Inc., Viracta Therapeutics, Inc.
Epstein-Barr Virus-Positive (EBV+) Relapsed/Refractory Lymphomas, Epstein-Barr Virus-Positive (EBV+) Relapsed/Refractory Lymphomas, Diseases [C] - Cancer [C04]
 
 
NCT02362997: Pembrolizumab After ASCT for Hodgkin Lymphoma, DLBCL and T-NHL

Completed
2
82
US
Pembrolizumab, Keytruda, MK-3475, SCH 900475
Dana-Farber Cancer Institute, Merck Sharp & Dohme LLC
Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Peripheral T-Cell Lymphoma
10/21
06/23
2016-004043-36: T cell therapy for patients with leukemia or lymphoma T cellsterapi för behandling av leukemi och lymfom.

Not yet recruiting
2
25
Europe
3rd generation anti-CD19 CAR T cells, 3rdCARTa19, Solution for infusion
Uppsala University, AFA Insurance AB
CD19+ B cell lymphoma or leukemia CD19+ B cells-malignitet, Leukemia and lymphoma, blood cell cancer Leukemi och lymfom, blodcancer, Diseases [C] - Cancer [C04]
 
 
2021-002150-91: A study of SAR444245 with or without other anticancer therapies for the treatment of adults and adolescents with relapsed or refractory B cell lymphoma (Master Protocol) Estudio de SAR444245 con o sin otros tratamientos antineoplásicos para el tratamiento de adultos y adolescentes con linfoma de células B en recaída o refractario (protocolo principal).

Ongoing
2
60
Europe
SAR444245, Concentrate for solution for infusion, Keytruda
Sanofi-Aventis Recherche & Développement, Sanofi-Aventis Recherche & Développement
Classic Hodgkin LymphomaDiffuse large B-cell lymphoma Linfoma de Hodgkin clasicoLinfoma difuso de células B grandes en recaída o refractario, Lymphoma Linfoma, Diseases [C] - Cancer [C04]
 
 
2021-002570-54: AZD4573 as Monotherapy or in Combination with Anti-cancer Agents in Patients with r/r PTCL or r/r cHL AZD4573 in monoterapia o in combinazione con agenti antitumorali in pazienti con PTCL r/r o cHL r/r

Not yet recruiting
2
90
Europe
AZD4573, [AZD4573], Concentrate for solution for injection/infusion
ASTRAZENECA AB, AstraZeneca AB
- Relapsed/refractory Peripheral T-cell Lymphoma- Relapsed/refractory Classical Hodgkins Lymphoma - Linfoma a cellule T periferico recidivante/refrattario- Linfoma di Hodgkin classico recidivante/refrattario, Cancer (lymphoma) Cancro (linfoma), Diseases [C] - Blood and lymphatic diseases [C15]
 
 
LATENT, NCT03357757: Avelumab With Valproic Acid in Virus-associated Cancer

Active, not recruiting
2
39
Canada
Valproic Acid, Avelumab
AHS Cancer Control Alberta, EMD Serono
Cancer That is Associated With a Chronic Viral Infection, p16 Positive SCCHN, Squamous Cell Carcinoma of the Cervix, p16 Positive Squamous Cell Carcinoma of the Vagina or Vulva, p16 Positive Squamous Cell Carcinoma of the Penis, p16 Positive Squamous Cell Carcinoma of the Anus or Anal Canal, EBER Positive NPC, EBER Positive Hodgkins and Non-hodgkins Lymphona
03/22
02/27
NCT03436862: Nivolumab Maintenance Therapy After Autologous Stem Cell Transplant in Hodgkin Lymphoma Pts at Relapse/Progression Risk

Completed
2
37
US
Nivolumab, Opdivo
SCRI Development Innovations, LLC, Bristol-Myers Squibb
Hodgkin Lymphoma
05/22
04/23
AVENuE, NCT03617666: Avelumab in the Frontline Treatment of Advanced Classical Hodgkin Lymphoma - a Window Study

Active, not recruiting
2
49
Europe, RoW
Avelumab, Bavencio
University College, London, Pfizer
Hodgkin Lymphoma
07/22
05/25
SGN35-027, NCT03646123 / 2020-004027-17: Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma

Checkmark Part B and Part C data from SGN35-027 study in combination with Opdivo for classical Hodgkin Lymphoma at ASH 2022
Dec 2022 - Dec 2022: Part B and Part C data from SGN35-027 study in combination with Opdivo for classical Hodgkin Lymphoma at ASH 2022
Active, not recruiting
2
255
Europe, US, RoW
brentuximab vedotin, Adcetris, SGN-35, doxorubicin, vinblastine, dacarbazine, G-CSF, filgrastim, pegfilgrastim, nivolumab, Opdivo
Seagen Inc., Bristol-Myers Squibb
Hodgkin Lymphoma
11/22
06/26
TIRHOL, NCT04318080 / 2019-002105-22: Tislelizumab in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma

Active, not recruiting
2
46
Europe, US, RoW
Tislelizumab, BGB-A317
BeiGene, Lymphoma Study Association
Classical Hodgkin Lymphoma
12/22
09/24
NCT05472610: Study of Efficacy of BZ019 in Large B-cell Lymphoma

Recruiting
2
36
RoW
BZ019
Shanghai Mengchao Cancer Hospital, Shanghai Cell Therapy Group Co.,Ltd
Large B-cell Lymphoma
01/23
01/23
NCT04052997 / 2018-002556-32: Study to Evaluate the Efficacy and Safety of Camidanlumab Tesirine (ADCT-301) in Patients With Relapsed or Refractory Hodgkin Lymphoma

Completed
2
117
Europe, Canada, US, RoW
Camidanlumab Tesirine, ADCT-301
ADC Therapeutics S.A.
Relapsed Hodgkin Lymphoma, Refractory Hodgkin Lymphoma
01/23
01/23
ANIMATE, NCT03337919: Phase II Study of Nivolumab Monotherapy for Relapsed/Refractory Hodgkin Lymphoma

Active, not recruiting
2
78
Europe
Nivolumab, Opdivo®
University College, London, Bristol-Myers Squibb
Hodgkin Lymphoma
03/23
02/26
2021-005950-27: Imaging study with brentuximab in patients with lymphoma Beeldvormend onderzoek met brentuximab bij patiënten met lymfeklierkanker

Not yet recruiting
2
20
Europe
[89Zr] - Brentuximab, Solution for injection
University Medical Center Groningen, Takeda Pharmaceutical Company Ltd
All patients with histologically proven CD30-positive (i.e. > 1% cells) lymphomas who will be treated with brentuximab vedotin, including:Hodgkin lymphoma, T-cell lymphoma, Cutaneous T-cell lymphoma, DLBCL Alle patiënten met histologisch bewezen CD30-positieve (d.w.z. > 1% cellen) lymfomen die zullen worden behandeld met brentuximab vedotin, waaronder: Hodgkin-lymfoom, T-cellymfoom, Cutaan T-cellymfoom, DLBC, Patients with Lymphoma Patiënten met lymfeklierkanker:, Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Investigative Techniques [E05]
 
 
NCT01811368: Zevalin Before Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma

Active, not recruiting
2
20
US
rituximab, IDEC-C2B8, Mabthera, Rituxan, ibritumomab tiuxetan, Zevalin, anti-thymocyte globulin, ATG, ATGAM, lymphocyte immune globulin, Thymoglobulin, total nodal irradiation, TLI, total lymphoid irradiation, peripheral blood stem cell transplantation, PBPC transplantation, PBSC transplantation, peripheral blood progenitor cell transplantation, transplantation, peripheral blood stem cell, allogeneic hematopoietic stem cell transplantation, cyclosporine, cyclosporin, cyclosporin A, CYSP, Sandimmune, mycophenolate mofetil, Cellcept, MMF
Joseph Tuscano, Spectrum Pharmaceuticals, Inc
Refractory Non Hodgkin Lymphoma, Relapsed Non Hodgkin Lymphoma
04/23
12/23
SGN35-015, NCT01716806 / 2019-003982-17: A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL)

Checkmark Additional data for front-line Hodgkin's lymphoma in elderly patients (ASH 2014)
Nov 2014 - Nov 2014: Additional data for front-line Hodgkin's lymphoma in elderly patients (ASH 2014)
Checkmark For newly diagnosed Hodgkin's lymphoma in elderly patients
Dec 2013 - Dec 2013: For newly diagnosed Hodgkin's lymphoma in elderly patients
Checkmark ASH 2013
More
Completed
2
131
Canada, US
brentuximab vedotin, Adcetris; SGN-35, bendamustine, dacarbazine, nivolumab
Seagen Inc., Bristol-Myers Squibb
Hodgkin Disease, Peripheral T Cell Lymphoma
04/23
09/23
NCT04478123: Using Romiplostim to Treat Low Platelet Counts Following Chemotherapy and Autologous Hematopoietic Cell Transplantation in People With Blood Cancer

Completed
2
62
US
Romiplostim
Memorial Sloan Kettering Cancer Center, Amgen
Multiple Myeloma, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, HDT-AHCT
06/23
06/23
NCT05140382: AZD4573 as Monotherapy or in Combinations With Anti-cancer Agents in Patients With r/r PTCL or r/r cHL

Completed
2
52
Europe, US, RoW
AZD4573
AstraZeneca
Relapsed/Refractory Peripheral T-cell Lymphoma, Relapsed/Refractory Classical Hodgkins Lymphoma
08/23
02/24
KEYNOTE-C39, NCT05179603 / 2021-002150-91: A Study of SAR444245 With or Without Other Anticancer Therapies for the Treatment of Adults and Adolescents With Relapsed or Refractory B Cell Lymphoma (Master Protocol) [Pegathor Lymphoma 205]

Active, not recruiting
2
14
Europe, RoW
THOR-707, Pembrolizumab, KEYTRUDA® or generic
Sanofi, Merck Sharp & Dohme LLC
Classic Hodgkin Lymphoma, Diffuse Large B-cell Lymphoma
09/23
01/25
KEYNOTE-087, NCT02453594 / 2014-004482-24: Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (MK-3475-087/)

Checkmark cHL - ASH 2016
Dec 2016 - Dec 2016: cHL - ASH 2016
Checkmark EHA 2016
May 2016 - May 2016: EHA 2016
Checkmark ASCO 2016
More
Completed
2
211
NA
pembrolizumab, MK-3475, KEYTRUDA®
Merck Sharp & Dohme LLC
Hodgkin Lymphoma
09/23
09/23
KEYNOTE-C11, NCT05008224 / 2021-001244-95: Study of Safety and Efficacy of Pembrolizumab and Chemotherapy in Participants With Newly Diagnosed Classical Hodgkin Lymphoma (cHL) (MK-3475-C11/)

Checkmark Presentation of data from KEYNOTE-C11 trial for 1L Classic Hodgkin Lymphoma at ASH 2022
Nov 2022 - Nov 2022: Presentation of data from KEYNOTE-C11 trial for 1L Classic Hodgkin Lymphoma at ASH 2022
Completed
2
146
Europe, Canada, US, RoW
Pembrolizumab, MK-3475, SCH 900475, KEYTRUDA®, Doxorubicin, Adriamycin, DOXIL®, Rubex®, Vinblastine, Alkaban-AQ®, Velban®, Dacarbazine, Dtic-Dome®, Bleomycin, Blenoxane®, Etoposide, Toposar®, VePesid®, Etopophos®, VP-16, Etoposide phosphate, Cyclophosphamide, Neosar®, Cytoxan®, Vincristine, Oncovin®, Vincasar PFS®, Procarbazine, Matulane®, Prednisone, Liquid Pred®, Meticorten®, Orasone®, Deltasone®
Merck Sharp & Dohme LLC, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.,Inc
Classical Hodgkin Lymphoma
10/23
05/24
NCT04195633: Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies

Recruiting
2
60
US
Allogeneic Hematopoietic Stem Cell Transplantation, Allogeneic Hematopoietic Cell Transplantation, Allogeneic Stem Cell Transplantation, HSC, HSCT, Stem Cell Transplantation, Allogeneic, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Cyclosporine, 27-400, Ciclosporin, CsA, Cyclosporin, Cyclosporin A, Cyclosporine Modified, Gengraf, Neoral, OL 27-400, Sandimmune, SangCya, Filgrastim, G-CSF, Neupogen, r-metHuG-CSF, Recombinant Methionyl Human Granulocyte Colony Stimulating Factor, rG-CSF, Tevagrastim, Filgrastim-aafi, Nivestym, Fludarabine, Fluradosa, Mycophenolate Mofetil, Cellcept, MMF, Mycophenolate Sodium, ERL 080, ERL 080A, Socium Mycophenolate, Total-Body Irradiation, TBI, Total Body Irradiation, Whole Body Irradiation, Whole-Body Irradiation, SCT_TBI, Treosulfan, 1,2,3, 4-Butanetetrol, 1,4-dimethanesulfonate, [R-(R*,S*)]-, Dihydroxybusulfan, Ovastat, Treosulphan, Tresulfon
Fred Hutchinson Cancer Center, medac GmbH
Acute Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Adult Diffuse Large Cell Lymphoma, Anaplastic Large Cell Lymphoma, Burkitt Lymphoma, Chronic Myeloid Leukemia, BCR-ABL1 Positive, Chronic Myelomonocytic Leukemia, Hodgkin Lymphoma, Lymphoblastic Lymphoma, Lymphoplasmacytic Lymphoma, Mantle Cell Lymphoma, Mixed Phenotype Acute Leukemia, Myelodysplastic Syndrome, Prolymphocytic Leukemia, Refractory Chronic Lymphocytic Leukemia, Refractory Follicular Lymphoma, Refractory Marginal Zone Lymphoma, Refractory Small Lymphocytic Lymphoma
12/24
12/26
CheckMate 744, NCT02927769 / 2016-002347-41: A Study of Nivolumab Plus Brentuximab Vedotin in Patients Between 5 and 30 Years Old, With Hodgkin's Lymphoma (cHL), Relapsed or Refractory From First Line Treatment

Hourglass Feb 2021 - Dec 2021 : From CheckMate 744 trial for r/r classic hodgkin lymphoma
Checkmark FRom CheckMate 744 trial at ASH 2018 [screenshot]
Dec 2018 - Dec 2018: FRom CheckMate 744 trial at ASH 2018 [screenshot]
Active, not recruiting
2
72
Europe, Canada, US, RoW
Nivolumab, BMS-936558, Opdivo, brentuximab vedotin, bendamustine
Bristol-Myers Squibb, Seagen Inc.
Hodgkin Disease
06/24
11/24
NCT04938232: Ipilimumab With or Without Nivolumab in Relapsed/Refractory cHL

Active, not recruiting
2
13
US
Nivolumab, Opdivo, Ipilimumab, Yervoy
Dana-Farber Cancer Institute, Bristol-Myers Squibb
Hodgkin Lymphoma, Relapsed Hodgkin's Disease, Adult, Refractory Hodgkin Lymphoma
03/24
08/26
NCT06377566: A Study of BV-AVD in People With Bulky Hodgkin Lymphoma

Recruiting
2
71
US
Brentuximab vedotin, Doxorubicin, Vinblastine, Dacarbazine, Pembrolizumab, Gemcitabine, Vinorelbine, FDG-PET/CT scan
Memorial Sloan Kettering Cancer Center, Seagen Inc.
Hodgkin Lymphoma
04/27
04/27
NCT05346809: Isatuximab During Stem Cell Collection and Transplant in Patients With Multiple Myeloma and Lymphoma

Recruiting
2
39
US
Isatuximab, Sarclisa, Standard Procedures
Divaya Bhutani, Genzyme, a Sanofi Company
Lymphoma, Multiple Myeloma, Non-Hodgkin Lymphoma, Relapsed Hodgkin's Disease, Adult
03/25
03/25
NCT05180097: Pembrolizumab and Brentuximab Vedotin vs GDP and Stem Cell Transplant for Relapsed/Refractory Hodgkin Lymphoma

Recruiting
2
84
Canada
Gemcitabine, Dexamethasone, Cisplatin, Brentuximab vedotin, Pembrolizumab
Canadian Cancer Trials Group, Merck Sharp & Dohme LLC, Seagen Inc.
Hodgkin Lymphoma
06/25
06/26
NAVAL-1, NCT05011058: An Open-Label, Phase 2 Trial of Nanatinostat in Combination With Valganciclovir in Patients With Epstein-Barr Virus-Positive (EBV+) Relapsed/Refractory Lymphomas

Recruiting
2
140
Europe, Canada, US, RoW
Nanatinostat in combination with valganciclovir
Viracta Therapeutics, Inc.
Epstein-Barr Virus Associated Lymphoproliferative Disorder, EBV-Related PTLD, EBV Related Non-Hodgkin's Lymphoma, EBV-Positive DLBCL, NOS, EBV Associated Lymphoma, EBV Related PTCL, NOS
07/25
12/26
NCI-2018-02699, NCT03749018: Nivolumab With DA-REPOCH Chemotherapy Regimen in Treating Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma

Active, not recruiting
2
30
US
Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Doxorubicin Hydrochloride, 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8, 9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S-cis)- (9CI), ADM, Adriacin, Adriamycin, Adriamycin Hydrochloride, Adriamycin PFS, Adriamycin RDF, ADRIAMYCIN, HYDROCHLORIDE, Adriamycine, Adriblastina, Adriblastine, Adrimedac, Chloridrato de Doxorrubicina, DOX, DOXO-CELL, Doxolem, Doxorubicin.HCl, Doxorubin, Farmiblastina, FI 106, FI-106, hydroxydaunorubicin, Rubex, Etoposide, Demethyl Epipodophyllotoxin Ethylidine Glucoside, EPEG, Lastet, Toposar, Vepesid, VP 16-213, VP-16, VP-16-213, Nivolumab, BMS-936558, MDX-1106, NIVO, ONO-4538, Opdivo, Prednisone, .delta.1-Cortisone, 1, 2-Dehydrocortisone, Adasone, Cortancyl, Dacortin, DeCortin, Decortisyl, Decorton, Delta 1-Cortisone, Delta-Dome, Deltacortene, Deltacortisone, Deltadehydrocortisone, Deltasone, Deltison, Deltra, Econosone, Lisacort, Meprosona-F, Metacortandracin, Meticorten, Ofisolona, Orasone, Panafcort, Panasol-S, Paracort, PRED, Predicor, Predicorten, Prednicen-M, Prednicort, Prednidib, Prednilonga, Predniment, Prednisonum, Prednitone, Promifen, Servisone, SK-Prednisone, Rituximab, ABP 798, BI 695500, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, CT-P10, IDEC-102, IDEC-C2B8, IDEC-C2B8 Monoclonal Antibody, MabThera, Monoclonal Antibody IDEC-C2B8, PF-05280586, Rituxan, Rituximab Biosimilar ABP 798, Rituximab Biosimilar BI 695500, Rituximab Biosimilar CT-P10, Rituximab Biosimilar GB241, Rituximab Biosimilar IBI301, Rituximab Biosimilar PF-05280586, Rituximab Biosimilar RTXM83, Rituximab Biosimilar SAIT101, RTXM83, Vincristine Sulfate, Kyocristine, Leurocristine sulfate, Leurocristine, sulfate, Oncovin, Vincasar, Vincosid, Vincrex, Vincristine, sulfate
David Bond, MD, Bristol-Myers Squibb
Aggressive Non-Hodgkin Lymphoma, Ann Arbor Stage I Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma, Ann Arbor Stage II B-Cell Non-Hodgkin Lymphoma, Ann Arbor Stage II Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma, Ann Arbor Stage III B-Cell Non-Hodgkin Lymphoma, Ann Arbor Stage III Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma, Ann Arbor Stage IV B-Cell Non-Hodgkin Lymphoma, Ann Arbor Stage IV Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma, Diffuse Large B-Cell Lymphoma, High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements, High Grade B-Cell Lymphoma, Not Otherwise Specified, Indolent Non-Hodgkin Lymphoma, Mediastinal B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma, Transformed Non-Hodgkin Lymphoma
07/24
07/24
NCT03618550: Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma

Recruiting
2
69
US
pembrolizumab, gemcitabine, vinorelbine, liposomal doxorubicin, Stem cell mobilization and collection
Memorial Sloan Kettering Cancer Center, Merck Sharp & Dohme LLC
Hodgkin Lymphoma, Relapsed or Refractory Hodgkin Lymphoma
08/24
08/24
KEYNOTE B68, NCT04875195: A Study of Pembrolizumab (MK-3475) in Relapsed or Refractory Classical Hodgkin's Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL) (MK-3475-B68)

Active, not recruiting
2
66
Europe, Canada, US, RoW
Pembrolizumab, MK-3475, SCH 900475, KEYTRUDA®
Merck Sharp & Dohme LLC
Hodgkin's Lymphoma, Primary Mediastinal Large B-cell Lymphoma (PMBCL)
12/23
12/25
NCT04788043: Study of Magrolimab and Pembrolizumab in Relapsed or Refractory Classic Hodgkin Lymphoma

Active, not recruiting
2
8
US
Magrolimab, Hu5F9-G4, ONO-7913, anti-CD47 monoclonal antibody Hu5F9-G4, Pembrolizumab, Keytruda, MK-3475, SCH 900475, anti-PD-1 monoclonal antibody MK-3475, PET/CT, Positron Emission Tomography - Computed Tomography (PET/CT)
Stanford University, Merck Sharp & Dohme LLC
Hodgkin Lymphoma, Classic Hodgkin Lymphoma, Relapsed Classical Hodgkin Lymphoma, Refractory Classic Hodgkin Lymphoma
12/24
12/27
NAHL, NCT05723055: Evaluating Combination of Nivolumab and Axatilimab in Patients With Relapsed/Refractory Classical Hodgkin Lymphoma

Recruiting
2
9
US
Axatilimab, SNDX6532, Nivolumab, OPDIVO
University of Utah, Incyte Corporation
Hodgkin Lymphoma
04/25
04/28
CHARIOT, NCT04268706: Phase 2 Study Evaluating Autologous CD30.CAR-T Cells in Patients With Relapsed/Refractory Hodgkin Lymphoma

Active, not recruiting
2
97
US
CD30.CAR-T, Fludarabine, Fludara, Bendamustine, Bendeka
Tessa Therapeutics
Hodgkin Lymphoma, Adult, Hodgkin Disease Recurrent, Hodgkin Disease Refractory, Hodgkin Disease, Pediatric
05/25
03/37
NCT03179930: Combination Therapy With Entinostat and Pembrolizumab in Relapsed and Refractory Lymphomas

Active, not recruiting
2
47
US
Entinostat, Pembrolizumab
Memorial Sloan Kettering Cancer Center, Merck Sharp & Dohme LLC, Syndax Pharmaceuticals
Lymphoma, Relapsed, Refractory
06/25
06/25
NCT05900765: A Study of Zimberelimab(GLS-010) Combined With AVD for Newly Diagnosed Early-stage Hodgkin's Lymphoma

Recruiting
2
54
RoW
Zimberelimab 240mg, GLS-010
Sun Yat-sen University, Guangzhou Gloria Biosciences Co., Ltd.
Classical Hodgkin Lymphoma
06/25
06/26
NCT01508312: Brentuximab Vedotin (SGN-35) in Transplant Eligible Patients With Relapsed or Refractory Hodgkin Lymphoma

Checkmark ASCO 2016
May 2016 - May 2016: ASCO 2016
Completed
2
46
US
brentuximab vedotin (SGN-35), Brentuximab Vedotin (SGN-35)
Memorial Sloan Kettering Cancer Center, Seagen Inc., Hôpitaux Universitaires Henri Mondor, France
Hodgkin's Lymphoma
03/24
03/24
NCT05922904: PET Adapted Brentuximab Vedotin and Pembrolizumab in Combination With Doxorubicin and Dacarbazine in Classic Hodgkin Lymphoma

Recruiting
2
50
US
Brentuximab vedotin, Doxorubicin Hydrochloride, Adriamycin PFS®, Adriamycin RDF™, Adriamycin®, Rubex®, Pembrolizumab, SGN-35, Adcetris, Dacarbazine, DTIC-Dome®
M.D. Anderson Cancer Center, Merck Sharp & Dohme LLC, Seagen Inc.
Hodgkin Lymphoma
10/25
10/25
LuminICE-203, NCT05883449: Phase 2 Study of AFM13 in Combination With AB-101 in Subjects With R/R HL and CD30+ PTCL

Recruiting
2
154
US
AFM13, AB-101, Cyclophosphamide, Fludarabine, Interleukin-2
Affimed GmbH, Artiva Biotherapeutics, Inc.
Relapsed or Refractory Hodgkin Lymphoma, Peripheral T Cell Lymphoma
04/26
11/27
NCT03755804: Pediatric Classical Hodgkin Lymphoma Consortium Study: cHOD17

Recruiting
2
250
US
bendamustine, TREANDA (R), Etoposide, VP-16, Vepeside, Doxorubicin, Adriamycin (R), Bleomycin, Blenoxane (R), Vincristine, Oncovin (R), Vinblastine, Velban (R), Prednisone, Prednisolone, Filgrastim, Neupogen (R), Brentuximab Vedotin, Adcetris, Cyclophosphamide, Cytoxan (R), DTIC, DACARBAZINE (R), Dimethyl Triazeno Imidazole Carboximide, Quality of Life Measurements, Quality of Life Measurements (QOL), Radiotherapy, radiation therapy, irradiation
St. Jude Children's Research Hospital, Teva Pharmaceuticals USA, Seagen Inc.
Hodgkin Lymphoma
01/27
07/28
KEYNOTE-667, NCT03407144 / 2017-001123-53: Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/)

Active, not recruiting
2
340
Europe, US, RoW
pembrolizumab, MK-3475, doxorubicin, vinblastine, dacarbazine, cyclophosphamide, vincristine, prednisone/prednisolone, bleomycin, etoposide, Etoposide Phosphate, Radiotherapy (RT)
Merck Sharp & Dohme LLC
Hodgkin Lymphoma
02/27
02/27
NCT05404945: Fitness-adapted, Pembrolizumab-based Therapy for Untreated Classical Hodgkin Lymphoma Patients 60 Years of Age and Above

Recruiting
2
44
US
Pembrolizumab, Doxorubicin, Adriamycin, Vinblastine, Dacarbazine, Brentuximab vedotin
University of Virginia, Merck Sharp & Dohme LLC
Classical Hodgkin Lymphoma
10/27
10/27
RATiFY, NCT05627115: Response Adapted Incorporation of Tislelizumab Into the Front-line Treatment of Older Patients With Hodgkin lYmphoma

Not yet recruiting
2
80
NA
Tislelizumab, AVD, Radiotherapy, Response-adapted incorporation of tislelizumab
University College, London, BeiGene
Hodgkin Lymphoma
10/28
10/28
NCT05891821: Assessment of the Safety and Efficacy of Balstilimab for the Treatment of Relapsed/Refractory Lymphomas (IMMONC0001)

Recruiting
2
20
RoW
Balstilimab, AGEN2034
Immune Oncology Research Institute, Agenus Inc.
Lymphoma
09/29
09/29
2010-021086-73: HD-R3i - A study to improve the treatment of relapsed or refractory Hodgkin Lymphoma Patients using additional RAD001 (everolimus) to DHAP-chemotherapy HD-R3i - Eine Studie zur Verbesserung der Behandlung von rezidiverten oder refraktären Hodgkin Lymphom Patienten mittels Zugabe von RAD001 (everolimus) zur DHAP-Chemotherapie

Ongoing
1/2
73
Europe
everolimus, Tablet, Solution for infusion, Afinitor 2,5mg, dexamethasone, Afinitor 5,0mg
University of Cologne, Novartis Pharma GmbH
relapsed or refractory Hodgkin Lymphoma rezidiviertes oder refraktäres Hodgkin Lymphom, reappearance of Hodgkin Lymphoma or Hodgkin Lymphoma that did not respond to therapy Rückfall eines Hodgkin Lymphoms oder Hodgkin Lymphom, das auf Therapie nicht ansprach, Diseases [C] - Cancer [C04]
 
 
2019-001263-70: Immunotherapy with differentiated T lymphocytes genetically modified in patients with classic Hodgkin's lymphoma and non-Hodgkin's lymphoma T with CD30 expression Inmunoterapia con linfocitos T diferenciados modificados genéticamente en pacientes con linfoma de Hodgkin clásico y linfoma no-hodgkin T con expresión CD30

Not yet recruiting
1/2
30
Europe
Linfocitos HSP-CAR30, Infusion
Institut de Recerca H. de la Santa Creu i Sant Pau, Institut de Recerca H. de la Santa Creu i Sant Pau
Classic Hodgkin lymphoma and T-cell lymphoma with CD30 expression Linfoma de Hodgkin clásico y linfoma T con expresión CD30, Classic Hodgkin lymphoma and T-cell lymphoma with CD30 expression Linfoma de Hodgkin clásico y linfoma T con expresión CD30, Diseases [C] - Blood and lymphatic diseases [C15]
 
 
NCT02227199: Brentuximab Vedotin, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma

Active, not recruiting
1/2
45
US
Brentuximab Vedotin, ADC SGN-35, Adcetris, Anti-CD30 Antibody-Drug Conjugate SGN-35, Anti-CD30 Monoclonal Antibody-MMAE SGN-35, Anti-CD30 Monoclonal Antibody-Monomethylauristatin E SGN-35, cAC10-vcMMAE, SGN-35, Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Etoposide, Demethyl Epipodophyllotoxin Ethylidine Glucoside, EPEG, Lastet, Toposar, Vepesid, VP 16-213, VP-16, VP-16-213, Ifosfamide, Asta Z 4942, Asta Z-4942, Cyfos, Holoxan, Holoxane, Ifex, IFO, IFO-Cell, Ifolem, Ifomida, Ifomide, Ifosfamidum, Ifoxan, IFX, Iphosphamid, Iphosphamide, Iso-Endoxan, Isoendoxan, Isophosphamide, Mitoxana, MJF 9325, MJF-9325, Naxamide, Seromida, Tronoxal, Z 4942, Z-4942, Laboratory Biomarker Analysis
University of Washington, National Cancer Institute (NCI), Seagen Inc.
Recurrent Hodgkin Lymphoma, Refractory Hodgkin Lymphoma
03/20
09/25
C25004, NCT02979522 / 2015-004112-38: A Study of Brentuximab Vedotin + Adriamycin, Vinblastine, and Dacarbazine in Pediatric Participants With Advanced Stage Newly Diagnosed Hodgkin Lymphoma

Active, not recruiting
1/2
59
Europe, Japan, US, RoW
Brentuximab vedotin, Adcetris, Doxorubicin, Adriamycin, Vinblastine, Dacarbazine
Takeda
Hodgkin Disease
05/20
09/29
2016-002423-29: A Phase 1/2 Study of the Safety, Tolerability, and Efficacy of Epacadostat in Combination With Nivolumab in Select Advanced Cancers

Not yet recruiting
1/2
291
Europe
Epacadostat, Nivolumab, INCB024360, BMS-936558, Tablet, Solution for infusion, Opdivo
incyte Corporation, Incyte Corporation
Selected advanced cancers, including metastatic and/or unresectable solid tumors including NSCLC, melanoma,adenocarcinoma of the colon or rectum , recurrent squamous cell carcinoma of the head and neck, ovarian cancer, recurrent B cell NHL (including DLBCL) or HL, or glioblastoma., Selected advanced cancers including lung , melanoma, colon or rectum cancer, head and neck , ovarian , B cell non-Hodgkin's lymphoma or Hodgkin's lymphoma, or glioblastoma, Diseases [C] - Cancer [C04]
 
 
CheckMate 039, NCT01592370 / 2018-001030-17: An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in Patients With Multiple Myeloma

Checkmark AACR 2016 - relapsed or refractory lymphoid malignancies
Mar 2016 - Mar 2016: AACR 2016 - relapsed or refractory lymphoid malignancies
Checkmark ASH 2015
Nov 2015 - Nov 2015: ASH 2015
Checkmark ICML 2015
More
Active, not recruiting
1/2
316
Europe, US
Nivolumab, BMS-936558, Opdivo, Ipilimumab, Yervoy, BMS-734016, MDX010, Lirilumab, BMS-986015, Daratumumab, Darzalex, Pomalidomide, Pomalyst, Dexamethasone, Intensol
Bristol-Myers Squibb, Janssen, LP
Non-Hodgkin's Lymphoma, Hodgkin Lymphoma, Multiple Myeloma
09/20
12/23
2020-000354-10: A study to evaluate how safe is CC-220, how is the body affected by CC-220, and a preliminary idea on how CC-220 works, when given alone or together with a medicine to treat cancer, in patients with lymphoma that is not responding to treatment or that has re-appeared.

Not yet recruiting
1/2
232
Europe
Iberdomide, CC-220, Concentrate for concentrate for solution for infusion, Solution for injection, Capsule, hard, Mabthera, Gazyvaro
Celgene Corporation, Celgene Corporation
Relapsed or refractory lymphoma including the following subtypes:Aggressive B-cell lymphoma, follicular lymphoma, marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma and classical Hodgkin lymphoma., Different forms of type of blood cancer, called lymphoma, that is not responding to treatment or that has re-appeared., Diseases [C] - Blood and lymphatic diseases [C15]
 
 
NCT02891603: A Phase I/II GVHD Prevention Trial Combining Pacritinib With Sirolimus-Based Immune Suppression

Completed
1/2
40
US
Pacritinib, PAC, tyrosine kinase inhibitor (TKI), Sirolimus, Rapamune, Tacrolimus, Prograf, Allogenic hematopoietic cell transplant (alloHCT)
H. Lee Moffitt Cancer Center and Research Institute, CTI BioPharma, National Heart, Lung, and Blood Institute (NHLBI)
Graft Vs Host Disease, GVHD
01/22
04/22
2020-002927-13: Atezolizumab treatment together with the BEGEV regimen in patients with resistant Hodgkin's lymphoma and candidates for autologous stem cell transplantation. Trattamento di atezolizumab associato a combinazione BEGEV in pazienti con linfoma di Hodgkin resistente e candidati al trapianto autologo di cellule staminali.

Not yet recruiting
1/2
140
Europe
Atezolizumab, Bendamustina, Gemcitabina, Vinorelbina, [IMP2], [IMP3], [IMP4], [IMP5], [IMP6], [IMP1], Concentrate for solution for infusion, Powder for concentrate for solution for infusion, TECENTRIQ - 840 MG - CONCENTRATO PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO - FLACONCINO (VETRO) - 20 ML (60 MG/ML) - 1 FLACONCINO, BENDAMUSTINA ACCORD - 2,5 MG/ML POLVERE PER CONCENTRATO PER SOLUZIONE PER INFUSIONE - 5 FLACONCINI DA 40 ML, BENDAMUSTINA ACCORD - 2,5 MG/ML POLVERE PER CONCENTRATO PER SOLUZIONE PER INFUSIONE - 5 FLACONCINI DA 10 ML, Gemcitabina cloridrato, VINORELBINA ACTAVIS - 10 MG/ML CONCENTRATO PER SOLUZIONE PER INFUSIONE 1 FLACONCINO DI VETRO DA 5 ML, TECENTRIQ - 1200 MG - CONCENTRATO PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO - FLACONCINO (VETRO) - 20 ML (60 MG/ML) - 1 FLACONCINO
FONDAZIONE ITALIANA LINFOMI ONLUS, Roche S.p.A.
Refractory/relapsed Hodgkin Lymphoma. Linfoma di Hodgkin ricaduto/refrattario., Refractory/relapsed Hodgkin Lymphoma. Linfoma di Hodgkin ricaduto/refrattario., Diseases [C] - Blood and lymphatic diseases [C15]
 
 
2021-000493-29: Relatlimab + Nivolumab in Pediatric and Young Adult Lymphomas Relatlimab + nivolumab nei linfomi nella popolazione pediatrica e nei giovani adulti

Ongoing
1/2
99
Europe
Anti-LAG-3, NIVOLUMAB, [BMS-986016], [BMS-936558], Solution for injection/infusion, Concentrate for solution for injection/infusion, Opdivo
BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION, Bristol-Myers Squibb International Corporation, Bristol-Myers Squibb International Corporation
Recurrent or Refractory Classical Hodgkin Lymphoma and Non-Hodgkin Lymphoma Linfoma di Hodgkin classico e Linfoma Non-Hodgkin ricorrente o refrattario, Hodgkin Lymphoma and Non-Hodgkin Lymphoma Linfoma di Hodgkin e Linfoma Non-Hodgkin, Diseases [C] - Cancer [C04]
 
 
NCT05189093: Recombinant Humanized Anti-CD47/PD-1 Bifunctional Antibody HX009 in Patients With Relapsed/Refractory Lymphoma

Recruiting
1/2
99
RoW
Recombinant humanized anti-CD47/PD-1 bifunctional antibody HX009 injection
Waterstone Hanxbio Pty Ltd
Relapsed/Refractory Lymphoma
12/22
08/23
NCT04464798: A Dose Finding and Safety Study of CC-220, Alone and in Combination With an Anti-CD20 Monoclonal Antibody (mAb) in Subjects With Relapsed or Refractory Lymphomas

Active, not recruiting
1/2
62
Europe, US, RoW
CC-220, Iberdomide, Rituximab, Obinutuzumab
Celgene
Lymphoma
03/23
01/25
TAK-981-1501, NCT04074330: A Study of TAK-981 Given With Rituximab in Adults With Relapsed or Refractory CD20-Positive Non-Hodgkin Lymphoma

Terminated
1/2
38
Europe, Canada, Japan, US, RoW
TAK-981, Rituximab
Takeda
Lymphoma, Non-Hodgkin
04/23
04/23
2020-003946-36: Phase 1/2 Study of TAK-981 in Combination With Rituximab in Patients With Lymphoma

Not yet recruiting
1/2
180
Europe
NA, Rituximab, TAK-981, Concentrate for solution for infusion, MabThera
Takeda Development Center Americas, Inc., TAKEDA DEVELOPMENT CENTER AMERICAS INC., Takeda Development Center Americas, Inc. (TDC Americas)
Relapsed/Refractory CD20-Positive Non-Hodgkin Lymphoma, Lymphoma, Diseases [C] - Cancer [C04]
 
 
NCT05400876: To Evaluate the Safety and Efficacy of TQB2618 Injection Combined With Penpulimab in the Treatment of Patients With Relapsed and Refractory Lymphoma

Recruiting
1/2
92
RoW
TQB2618 injection, Penpulimab injection
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Relapsed/Refractory Lymphoma
05/23
10/23
NCT03187210: Brentuximab Vedotin and BeEAM High-dose Chemotherapy in Lymphomas

Suspended
1/2
20
Europe
Brentuximab Vedotin, BeEAM Regimen
Insel Gruppe AG, University Hospital Bern, Mundipharma Medical Company
Lymphoma
11/23
11/24
KEYNOTE-877, NCT03674567: Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination With Pembrolizumab

Active, not recruiting
1/2
323
US, RoW
FLX475, pembrolizumab (KEYTRUDA®)
RAPT Therapeutics, Inc., Merck Sharp & Dohme LLC
Advanced Cancer
09/24
01/25
NCT03576378 / 2017-003689-28: BrEPEM-LH-22017 for Older Patients With Untreated Hodgkin Lymphoma (HL)

Active, not recruiting
1/2
41
Europe
BrentuximabVedotin (BV), cyclophosphamide, procarbazine, prednisone, etoposide, mitoxantrone
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea, Takeda
Hodgkin Lymphoma
10/23
10/24
NCT03739619: Gemcitabine, Bendamustine, and Nivolumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma

Active, not recruiting
1/2
54
US
Bendamustine, Bendamustine Hydrochloride, Cytostasan Hydrochloride, Levact, Ribomustin, SyB L-0501, Treanda, Gemcitabine, dFdC, dFdCyd, Difluorodeoxycytidine, Nivolumab, BMS-936558, MDX-1106, NIVO, ONO-4538, Opdivo
Emory University, Bristol-Myers Squibb, National Cancer Institute (NCI), National Institutes of Health (NIH)
Recurrent Hodgkin Lymphoma, Refractory Hodgkin Lymphoma, Classical Hodgkin Lymphoma, Hodgkin Lymphoma
12/24
12/24
NCT04622956: GVHD Prophylaxis With Methotrexate in Haploidentical HCT Using Posttransplant Cyclophosphamide

Recruiting
1/2
47
RoW
Methotrexate Injectable Solution, Fauldmetro [Libbs]
University of Sao Paulo General Hospital, Libbs Farmacêutica LTDA
Graft Vs Host Disease, Hematopoietic Neoplasm
12/23
12/25
 

Download Options